Baclofen: MedlinePlus Drug Information

pronounced as (bak’ loe fen)

To use the sharing features on this page, please enable JavaScript.

Baclofen is used to treat pain and certain types of spasticity (muscle stiffness and tightness) from multiple sclerosis, spinal cord injuries, or other spinal cord diseases. Baclofen is in a class of medications called skeletal muscle relaxants. Baclofen acts on the spinal cord nerves and decreases the number and severity of muscle spasms caused by multiple sclerosis or spinal cord conditions. It also relieves pain and improves muscle movement.

Baclofen comes as a tablet and a solution (liquid) to take by mouth. It usually is taken 3 times a day at evenly spaced intervals. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take baclofen exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Use an oral syringe (measuring device) to accurately measure and take your dose of baclofen solution. Ask your pharmacist for an oral syringe if one is not included with your medication.

Continue to take baclofen even if you feel well. Do not stop taking baclofen without talking to your doctor, especially if you have taken large doses for a long time. Abruptly stopping this medication can cause seizures, fever, confusion, muscle stiffness, or hallucinations. Your doctor probably will want to decrease your dose gradually.

This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.

Before taking baclofen,

• tell your doctor and pharmacist if you are allergic to baclofen, any other medications, or any of the ingredients in baclofen tablets and oral solution. Ask your pharmacist for a list of the ingredients.
• tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: antidepressants, medications for anxiety, medications for mental illness, medications for seizures, sedatives, sleeping pills, or tranquilizers. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
• tell your doctor if you have or have ever had epilepsy, a stroke, a rheumatic disease, cerebral palsy, Parkinson’s disease, a psychiatric condition such as schizophrenia or a confusional state, or kidney disease.
• tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking baclofen, call your doctor immediately.
• you should know that baclofen may make you drowsy. Do not drive a car or operate machinery until you know how this medication affects you.
• ask your doctor about the safe use of alcoholic beverages while you are taking baclofen. Alcohol can make the side effects from baclofen worse.

Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

Baclofen may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

• dizziness
• weakness
• confusion
• headache
• nausea
• constipation
• difficulty falling asleep or staying asleep
• tiredness
• frequent urination

Some side effects can be serious. If you experience either of the following symptoms, call your doctor immediately:

• seeing things or hearing voices that do not exist
• seizures

If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration’s (FDA) MedWatch Adverse Event Reporting program online (http://www. fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store the tablets at room temperature and away from excess heat and moisture (not in the bathroom). Store the oral solution in the refrigerator.

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA’s Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can’t be awakened, immediately call emergency services at 911.

Symptoms of overdose may include:

• vomiting
• weak muscle tone
• drowsiness
• vision problems
• coma
• difficulty breathing
• seizures

• Kemstro^®¶
• Lioresal^®¶
• Ozobax^®

^¶ This branded product is no longer on the market. Generic alternatives may be available.

Last Revised – 12/15/2019

Browse Drugs and Medicines

Baclofen Uses, Dosage & Side Effects

Generic name: baclofen (oral) [ BAK-loe-fen ]
Brand names: Lioresal, Lioresal Intrathecal, Gablofen, FIRST Baclofen, Ozobax, Fleqsuvy, Lyvispah
Dosage forms: oral granule (10 mg; 20 mg; 5 mg), oral liquid (5 mg/5 mL), oral suspension (1 mg/mL; 5 mg/mL), oral tablet (10 mg; 20 mg; 5 mg)
Drug class: Skeletal muscle relaxants

Medically reviewed by Kaci Durbin, MD. Last updated on Apr 19, 2023.

What is baclofen?

Baclofen belongs to a class of medications called skeletal muscle relaxants. Baclofen is an antispasmodic agent that acts on spinal cord nerves and decreases the number and severity of muscle spasms in patients with certain conditions affecting the spinal cord.

Baclofen is used in adults and children at least 12 years old to treat certain types of spasticity (muscle stiffness and tightness) and muscle pain in people with multiple sclerosis or a spinal cord injury or other spinal cord diseases.

Baclofen relieves pain and improves muscle movement.

Warnings

Do not use baclofen at a time when you need muscle tone for safe balance and movement during certain activities. Baclofen may make you drowsy. Do not drive or operate heavy machinery until you know how this medicine affects you.

Do not stop using this medicine suddenly, or you could have unpleasant withdrawal symptoms.

Ask your doctor about the safe use of alcoholic beverages while you are taking baclofen. Alcohol can make the side effects from baclofen worse.

Before taking this medicine

You should not use this medicine if you are allergic to baclofen.

To make sure this medicine is safe for you, tell your doctor if you have ever had:

• mental illness or psychosis;

• epilepsy or other seizure disorder;

• problems with balance;

• cerebral palsy;

• Parkinson’s disease;

• schizophrenia or a confused state;

• high blood pressure, or fast heart rate;

• a rheumatic disease;

• a stroke or blood clot; or

• kidney disease.

Using baclofen may increase your risk of developing an ovarian cyst. Talk with your doctor about your own risk.

Tell your doctor if you are pregnant or plan to become pregnant, or breastfeeding or plan to breastfeed. If you take baclofen while pregnant or breastfeeding, withdrawal symptoms such as tremors, stiff muscles, or seizure may occur in the baby.

How should I take baclofen?

Take baclofen exactly as prescribed by your doctor. Follow all directions on your prescription label and read all medication guides or instruction sheets. Your doctor may occasionally change your dose.

Shake the oral suspension (liquid).

Measure a dose with the supplied measuring device (not a kitchen spoon).

Shake and pour the entire oral granules packet to dissolve in your mouth or swallow whole at once, with or without liquids.

You may also mix the granules with liquids (milk, or apple juice) or soft food (apple sauce, yogurt, or pudding).

The oral granules can also be given through a feeding tube. Ask your doctor or pharmacist if you do not understand these instructions.

Call your doctor if your symptoms do not improve, or if they get worse.

You may have withdrawal symptoms if you stop using baclofen suddenly. Ask your doctor before stopping the medicine.

Store the oral suspension (liquid) at room temperature away from moisture and heat. Throw Fleqsuvy away after 2 months of first opening.

Store Ozobax in the refrigerator, do not freeze.

Dosing information

Usual Adult Dose for Spasticity:

Oral:
-Initial dose: The following gradually increasing dosage regimen is suggested, but should be adjusted to suit individual patient requirements: 5 mg orally 3 times a day for 3 days, then 10 mg orally 3 times a day for 3 days, then 15 mg orally 3 times a day for 3 days, then 20 mg orally 3 times a day for 3 days
-Maintenance dose: Should be individualized.
-Maximum dose: 80 mg/day (20 mg orally 4 times a day).

Usual Pediatric Dose for Spasticity:

12 years and older:
Oral:
-Initial dose: The following gradually increasing dosage regimen is suggested, but should be adjusted to suit individual patient requirements: 5 mg orally 3 times a day for 3 days, then 10 mg orally 3 times a day for 3 days, then 15 mg orally 3 times a day for 3 days, then 20 mg orally 3 times a day for 3 days
-Maintenance dose: Should be individualized.
-Maximum dose: 80 mg/day (20 mg orally 4 times a day)

Comments:
-The lowest dose compatible with an optimal response is recommended.
-Slowly withdraw therapy if benefits are not evident after a reasonable period.

What happens if I miss a dose?

Take the medicine as soon as you can, but skip the missed dose if it is almost time for your next dose. Do not take two doses at one time.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include increasing drowsiness, dizziness, sleepiness, trouble focusing on objects, shallow breathing, seizure, or muscle weakness leading to loss of consciousness.

What should I avoid while taking baclofen?

Avoid drinking alcohol.

Avoid driving or hazardous activity until you know how baclofen will affect you. Your reactions could be impaired.

Do not share this medicine with another person, even if they have the same symptoms you have.

Baclofen side effects

Get emergency medical help if you have signs of an allergic reaction to baclofen: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Baclofen may cause serious side effects. Call your doctor at once if you have:

• severe drowsiness, breathing problems;

• confusion, hallucinations;

• muscle weakness, itching, tingling, or twitching in your hands, arms, feet, or legs; or

• fever.

Common baclofen side effects may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect baclofen?

Using baclofen with other drugs that make you drowsy can worsen this effect. Ask your doctor before using opioid medication, a sleeping pill, a muscle relaxer, or medicine for anxiety or seizures.

Other drugs may interact with baclofen, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

Popular FAQ

Common antidepressants used for orthopedic pain relief may include SSRIs like fluoxetine (Prozac), paroxetine (Paxil), and sertraline (Zoloft), SNRIs such as duloxetine (Cymbalta), or tricyclic antidepressants (TCAs) like amitriptyline (Elavil) or nortriptyline (Pamelor). Continue reading

More about baclofen

• Check interactions
• Compare alternatives
• Reviews (426)
• Drug images
• Side effects
• Dosage information
• Patient tips
• During pregnancy
• Support group
• Drug class: skeletal muscle relaxants
• Breastfeeding

Patient resources

• Advanced Reading
• Baclofen (Oral) (Advanced Reading)
• Baclofen Intrathecal Injection
• Baclofen Tablets
• Baclofen Oral Solution

Other brands

Lioresal, Gablofen, Fleqsuvy, Lyvispah, Ozobax

Professional resources

• Prescribing Information

Related treatment guides

• Alcohol Withdrawal
• Cerebral Spasticity
• Cervical Dystonia
• Chronic Spasticity

Further information

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use baclofen only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Copyright 1996-2023 Cerner Multum, Inc. Version: 9.01.

Baclosan (Baclofen): what kind of drug is it, how does it work, signs of use, consequences, addiction treatment

In modern realities, more and more people are pathologically dependent on various synthetic drugs. The universal availability of these drugs only increases the risk of developing drug addiction. Some of the drugs hunted by drug addicts are widely used in traditional medicine for the treatment and correction of various pathological conditions.

Baclofen – pills for treatment or drug?

Baclosan (Baclofen) is a synthetic drug that belongs to the group of muscle relaxants. It is used in traditional medical practice to relieve seizures of epilepsy, correct spastic reactions in various muscle groups that are provoked by various diseases. But, unfortunately, baclofen is a drug that is widely popular in the criminal world. The pathological interest in this drug is explained by the mechanism of action of Baclofen on the central nervous system.

What does the drug do to a person that the frequency of pathological addictions to these pills regularly increases:

• dulls mental reactions, reduces the effect of external stimuli on the receptors of the nervous system;
• promotes hallucinations;
• helps to relax and get rid of fatigue;
• improves mood and resistance to stress;
• relieves muscle spasms.

Traditional neurology and neurosurgery recommend the use of Baclofen for medicinal purposes. What doctors prescribe medicine for:

• spastic processes;
• epilepsy;
• traumatic brain injury;
• spinal cord surgery.

The systematic use of baclofen tablets leads to the formation of receptor resistance at the biochemical level. Therefore, the patient constantly requires increasing dosages of the drug to obtain the desired effect. Drug addicts constantly increase the amount of the drug baclofen. What is the unauthorized use of the drug leads to irreversible consequences, drug addicts do not even think about it.

Drug abuse leads to receptor resistance to regular use of Baclofen tablets. An overdose against the background of a significant excess of the doses recommended by the doctor occurs almost instantly and is manifested by the following symptoms:

Treatment of addiction to baclofen

consultation with a narcologist at home and in a hospital

removal of withdrawal symptoms

we work around the clock

free consultation

Leave a request and we will call you back 90 011 after 1 minute

8 (495) 150-85-96

Or call

Baclofen drug.

Effect of unauthorized use

Baclofen is widely used in the criminal environment. The effect of the drug on the central nervous system, which is manifested by a decrease in the reactivity of nervous processes, explains the use of the drug to achieve the effect of euphoria. The drug has a pronounced sedative effect, increases adaptation to stress factors. The systematic use of the remedy leads to:

• resistance to stress factors;
• cheer up;
• achieve the effect of euphoria.

Balcofen. Consequences of illegal use

CNS suppression is often negative and can lead to irreversible consequences:

• heart failure;
• stop spontaneous breathing;
• disorders of the nervous regulation of vital organs;
• the appearance of malignant tumors in the central and peripheral nervous system.

In addition, a significant excess of dosages recommended by specialists leads to negative consequences from taking Baclofen tablets. Side effects at high doses:

• gastrointestinal bleeding;
• severe intoxication;
• acute renal or hepatic insufficiency;
• memory problems;
• loss of consciousness;
• acute heart failure;
• convulsions that are difficult to control.

These negative reactions are due to the action of Baclofen on nerve cells. Overdose develops quickly enough. This is due to the specific effect of the main drug on nerve receptors. This condition requires urgent specialized care to prevent negative consequences and death.

Only in the conditions of a specialized clinic can one get rid of the biochemical and psycho-emotional dependence on baclosan and its derivatives.

Call 8 (495) 150-85-96

Baclofen: mechanisms of therapeutic and toxic action (review) | Romanova

1. Romanova O.L., Sundukov D.V., Golubev M.A., Blagonravov M.L., Goshkoev V.V., Churilov A.A. Pathological changes in the liver in acute poisoning with clozapine and its combination with ethanol (pilot study). General resuscitation. 2019; 15(2):27–35. DOI: 10.15360/1813-9779-2019-2-27-35

2. Livanov G.A., Lodyagin A.N., Razina A.A., Glushkov S.I., Ivanova A.A., Volchkova E.V., Batotsyrenov B.V. Favorable outcome of acute severe methadone poisoning (clinical observation). General resuscitation. 2018; 14(5):25–31. DOI: 10.15360/1813-9779-2018-5-25-31

3. Kuznetsov B.V., Lodyagin A.N., Batotsyrenov B.V., Nezhentseva I.V., Baranov D.V. Features of the clinical course of acute methadone poisoning complicated by the development of positional compression syndrome and systemic rhabdomyolysis. Toxicologist. messenger. 2015; 4:38–43.

4. Livanov G.A., Loladze A.T., Batotsyrenov B.V., Lodyagin A.N., Glushkov S.I., Kharitonova T.V., Ivanova A.A., Baranov D.V. ., Antonova A.M. Acute methadone (dolphin) poisoning (review). General resuscitation. 2017; 13(3):48–63. DOI: 10.15360/1813-9779-2017-3-48-63

5. Romanova O.L., Sundukov D.V., Golubev A.M., Blagonravov M.L. Morphological changes depending on the content of clozapine and its metabolites in the lungs and blood serum (experimental study). General resuscitation. 2018; 14(4):44–51. DOI: 10.15360/1813-9779-2018-4-44-51

6. Hendry-Hofer T., Ng P., Witeof A., Mahon S., M. Brenner, Boss G., V. Bebarta A Review on Ingested Cyanide: Risks, Clinical Presentation, Diagnostics, and Treatment Challenges. J Med Toxicol. 15(2): 128–133. PMID: 30539383. PMCID: PMC6441064. (available on 2020-04-01) DOI: 10.1007/s13181-018-0688-y

7. Anseeuw K., Delvau N., Burillo-Putze G., De Iaco F., Geldner G., Holmström P. , Lambert Y; Sabbe M. Cyanide poisoning by fire smoke inhalation: a European expert consensus. European Journal of Emergency Medicine. 2013; 20(1):2–9. DOI: 10.1097/mej.0b013e328357170b. PMID 22828651.

8. Baclofen Monograph for Professionals. drugs.com. American Society of Health-System Pharmacists. Retrieved March 3, 2019.

9. Product Information Clofen. TGA eBusiness Services. Millers Point, Australia: Alphapharm Pty Limited. 7 June 2017. Retrieved 15 August 2017

10. Mashkovsky M. D. Medicinal products. 17th ed. M.: Novaya volna; 2019: 73–74. [In Russ.].

11. Issa S.Y., Hafez E.M., El-Banna A.S., Abdel Rahman S.M., AlMazroua M.K., El-Hamd M.A. Baclofen Systemic Toxicity: An Experimental Histopathological and Biochemical Study. Hum Exp Toxicol. 2018, 37(4): 431–441. PMID: 28565970. DOI: 10.1177/0960327117712369

12. Reynolds K., Kaufman R., Korenoski A., Fennimore L., Shulman J., Lynch M. Trends in gabapentin and baclofen exposures reported to U.S. poison centers. clinical toxicology. 2019; 1–10. DOI: 10.1080/15563650.2019.1687902. ISSN 1556-3650. PMID 31786961.

13. Charifou Y., Martinet O., Jabot J., Gauzere B.A., Allyn J., Vandroux D. Baclofen Intoxication Cases in an Intensive Care Unit. Anaesth Crit Care Pain Med, 2016; 35(2): 169–170. PMID: 26667597 DOI: 10.1016/j.accpm.2015.10.003

14. Dukova O.A., Pokrovskij A.A., Melent’ev A.B., Krasnov E.A., Suvorova E.V., Efremov A.A. Sudebno-meditsinskaya ekspertiza. 2015; 58(1): 35–39. [In Russ.]. DOI: 10.17116/sudmed201558135-39

15. Mofiat A.C., Osselton M.D., Widdop B. (eds.) Clarke’s analysis of drugs and poisons. London: Pharmac Press 2011.

16. Kapil V., Green J.L., Le Lait M., Dargan P.I. Misuse of the c-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. Br J Clin Pharmacol. 2014; 78(1):190–191. PMID: 25083536. PMCID: PMC4168395. DOI: 10.1111/bcp.12277

17. Slavova S., Miller A., ​​Bunn T.L., White J.R., Kirschke D., Light T., Christy D., Thompson G. Winecker R. Prevalence of gabapentin in drug overdose postmortem toxicology testing results. Drug Alcohol Depend. 2018 May 1; 186:80–85. PMID: 29554591. DOI: 10.1016/j.drugalcdep.2018.01.018

18. Beraha, E., Bodewits, P., van den Brink, W., Wiers, R. Speaking fluently with baclofen? BMJ Case Reports. 2017.bcr-2016. DOI: 10.1136/bcr2016-218714.

19. Smith R.V., Lofwall M.R., Havens J.R. Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky. Am J Psychiatry. 2015; 172(5): 487–488. DOI: 10.1176/appi.ajp.2014.14101272.

20. Brayfield A, ed. (January 9, 2017). Baclofen: Martindale: The Complete Drug Reference. MedicinesComplete. London, UK: Pharmaceutical Press. Retrieved 15 August 2017.

21. Smith R., Havens J., Walsh S. Gabapentin misuse, abuse and diversion: a systematic review. addiction. 2016; 111(7): 1160–1174. DOI: 10.1111/add.13324

22. de Marcellus C.., le Bot S., Decleves X., Baud F., Renolleau S., Oualha M. Report of severe accidental baclofen intoxication in a healthy 4year-old boy and review of the literature. Arch Pediatrician. 2019; 26(8): 475–478. DOI: 10.1016/j.arcped.2019.10.003.

23. Weißhaar G.F., Hoemberg M., Bender K., Bangen U., Herkenrath P., Eifinger F., Rothschild M., Roth B., Oberthuer A. Baclofen intoxication: a “fun drug” causing deep coma and nonconvulsive status epilepticus–a case report and review of the literature. Eur J Pediatr. 2012; 171(10): 1541–1547. PMID: 22729246. DOI: 10.1007/s00431-012-1780-y

24. Tagirov A.A., Larionov S.S. Acute intentional poisoning with the drug “Baclofen” in adolescents. Uspekhi modern estestvoznaniya.2014; 6:94–94. [In Russ.].

25. Agabio R.; Preti A.; Gessa G.L. Efficacy and Tolerability of Baclofen in Substance Use Disorders: A Systematic Review. European Addiction Research. 2013; 19(6): 325–345. DOI: 10.1159/000347055. ISSN 1421-9891. PMID 23775042.

26. Thill C., Di Constanzo L., Pessey F., Aries P., Montelescaut É., Sapin J., Vaillant C., Drouillard I. Usefulness of Plasma Drug Monitoring in Severe Baclofen Poisoning. Clin Toxicol (Phila). 2015; 53 (9): 923-924. PMID: 26415080. DOI: 10.3109/15563650.2015.1088158

27. Gablofen (Baclofen) FDA Full Prescribing Information. US Food and Drug Administration. Retrieved 2016-01-2

28. Rolland B., Paille F., Gillet C., Rigaud A., Moirand R., Dano C., Dematteis M., Mann K., Aubin H.J. Pharmacotherapy for alcohol dependence: the 2015 recommendations of the French Alcohol Society, issued in partnership with the European Federation of Addiction Societies. CNS Neurosci Ther. 2016; 22:25–37. PMID: 26768685. PMCID: PMC6492872. DOI: 10.1111/cns.12489

29. Reynaud M., Aubin H-J., Trinquet F., Zakine B., Dano C., Dematteis M., Trojak B., Paille F., Detilleux M.. A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients—the ALPADIR study. Alcohol Alcohol. 2017; 52:439–446. PMID: 28525555. DOI: 10.1093/alcalc/agx030

A. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 2015; 25:1167–1177. PMID: 26048580. DOI: 10.1016/j.euroneuro.2015.04.002

31. Rigal L., Legay Hoang L., Alexandre-Dubroeucq C., Pinot J., Le Jeunne C., Jaury P. Tolerability of high-dose baclofen in the treatment of patients with alcohol disorders: a retrospective study. Alcohol Alcohol. 2015; 50:551–557. DOI: 10.1093/alcalc/agv052

32. Léger M, Brunet M, Le Roux G, Lerolle N, Boels D. Baclofen self-poisoning in the era of changing indication: multicentric reports to a French poison control centre. Alcohol Alcohol. 2017; 52:665–670. DOI: 10.1093/alcalc/agx072

33. Franchitto N., De Haro L., Pélissier F. Focusing solely on the effect of the medication without taking a holistic view of the patient does not seem very constructive. Clin Toxicol. 2018; 56: 309. DOI: 10.1080/15563650.2017.1373781

34. Beck A., Pelz P., Lorenz R.C., Charlet K., Geisel O., Heinz A., Wüstenberg T., Müller C.A. Effects of High-Dose Baclofen on Cue Reactivity in Alcohol Dependence: A Randomized, Placebo-Controlled pharmacofMRI Study. Eur Neuropsychopharmacol. 2018; 28 (11): 1206–1216 PMID: 30217552. DOI: 10.1016/j.euroneuro.2018.08.507

35. Vourc’h M., Feuillet F., Mahe P.-J., Sebille V., Asehnoune K., BACLOREA trial group Baclofen to Prevent Agitation in Alcohol-Addicted Patients in the ICU: Study Protocol for a Randomised Controlled trial. trials. 2016; 17(1): 415. PMID: 27542731. PMCID: PMC4992221. DOI: 10.1186/s13063-016-1539-2

36. Dixit D., Endicott J., Burry L., Ramos L. , Yeung S.Y.A., Devabhakthuni S., Chan C., Tobia A., Bulloch M.N. Management of Acute Alcohol Withdrawal Syndrome in Critically Ill Patients. pharmaceutical therapy. 2016; 36(7):797–822. PMID: 27196747. DOI: 10.1002/phar.1770

., Defourny H., van Tricht M., van den Brink W., Wiers R.W. Efficacy and safety of highdose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology.2016; 26(12): 1950–1959. DOI: 10.1016/j.euroneuro.2016.10.006. PMID 27842939.

38. Minozzi S., Saulle R., Rösner S. Baclofen for alcohol use disorder. Cochrane Database Syst Rev. 2018; 26 (11): CD012557. PMID: 30484285. PMCID: PMC6517285. DOI: 10.1002/14651858.CD012557.pub2

39. Girish K., Vikram Reddy K., Pandit L.V., Pundarikaksha H.P., Vijendra R., Vasundara K., Manjunatha R., Nagraj M., Shruthi R. A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome. Biomed J. 2016; 39(1): 72–80. DOI: 10.1016/j.bj.2015.09.002. PMID: 27105601 PMCID: PMC6138810

40. Simon N., Franchitto N., Rolland B. Pharmacokinetic Studies of Baclofen Are Not Sufficient to Establish an Optimized Dosage for Management of Alcohol Disorder. Front Psychiatry. 2018; 9:485. PMID: 30349489. PMCID: PMC6186984. DOI: 10.3389/fpsyt.2018.00485

41. Schiess M.C., Eldabe S., Konrad P., Molus L., Spencer R., Stromberg K., Weaver T., Punkett R. Intrathecal Baclofen for Severe Spasticity: Longitudinal Data From the Product Surveillance Registry. neuromodulation. 2020. DOI: 10.1111/ner.13097. [Epub ahead of print] PMID: 31989725

42. van den Brink W. Baclofen: A Game Changer in the Treatment of Alcohol Dependence. Alcohol Alcohol. 2020; 55(1): 46–47. DOI: 10.1093/alcalc/agz085. PMID: 32031207

43. E. M. Krupitsky, K. V. Rybakova, A. S. Kiselev, Yu. Yu.V., Neznanov N.G. Efficacy and safety of baclofen in the treatment of alcohol dependence (double-blind, randomized, placebo-controlled pilot study). Journal of Neurology and Psychiatry. S.S. Korsakov. 2015; 115(6):53–62. DOI: 10.17116/jnevro20151156153-62

44. McLaughlin M.J., He Y., Brunstrom-Hernandez J., Thio L.L., Carleton B.C., Ross C.J.D., Gaedigk A., Lewandowski A., Dai H., Jusko W.J., Leeder J.S. Response in Children With Cerebral Palsy PM R. 2018; 10(3):235–243. DOI: 10.1016/j.pmrj.2017.08.441.

45. Navarrete-Opazo A.A., Gonzalez W., Nahuelhual P. Effectiveness of Oral Baclofen in the Treatment of Spasticity in Children and Adolescents With Cerebral Palsy. Arch Phys Med Rehabil 2016; 97(4): 604–618. DOI: 10.1016/j.apmr.2015.08.417. PMID: 26321489

46. Furr-Stimming E., Boyle A.M., Schiess M.C. Spasticity and Intrathecal Baclofen. Semin Neurol 2014; 34:591–596. PMID: 5520030 DOI: 10.1055/s-0034-1396012

Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl). 2010; 211(2): 233–244. DOI: 10.1007/s00213-010-1888-6.

48. Kampman, K. M.. New medications for the treatment of cocaine dependence. Psychiatry (Edgmont), 2005; 2(12): 44–48. PMC 2994240. PMID 21120115.

49. Froestl W. GABA Receptor Pharmacology – A Tribute to Norman Bowery. Advances in Pharmacology. 2010:58:19–62. ISBN 978-0-12378647-0. DOI: 10.1016/S1054-3589(10)58002-5.

50. Yogeeswari P., Ragavendran J.V., Sriram D. An update on GABA analogs for CNS drug discovery. Recent patents on CNS drug discovery. 2006; 1(1):113–118. PMID 18221197. DOI: 10.2174/157488906775245291.

51. Mezler M., Müller T., Raming K. Cloning and functional expression of GABA (B) receptors from Drosophila. Eur. J. Neurosci. 2001; 13(3): 477–486. PMID 11168554. DOI: 10.1046/j.1460-9568.2001.01410.x.

52. Carter L.P., Koek W., France C.P. Behavioral analyzes of GHB: Receptor mechanisms. Pharmacol. Ther., 2008; 121(1): 100–114. DOI: 10.1016/j.pharmthera.2008.10.003.

53. Reis G.M., Duarte I.D. Baclofen, an agonist at peripheral GABAB receptors, induces antinociception via activation of TEA-sensitive potassium channels. Br J Pharmacol. 2006; 149(6): 733–739. DOI: 10.1038/sj.bjp.0706898

54. Zvejniece L., Vavers E., Svalbe B., Veinberg G., Rizhanova K., Liepins V., Kalvinsh I., Dambrova M. α2-δ subunit of voltage-dependent calcium channels and exerts gabapentin-like anti-nociceptive effects. Pharmacol. Biochem. behavior. 2015; 137:23–29. DOI: 10.1016/j.pbb.2015.07.014. PMID 26234470.

55. Potes C.S., Neto F.L., Castro-Lopes J.M. Administration of baclofen, a gamma-aminobutyric acid type B agonist in the thalamic ventrobasal complex, attenuates allodynia in monoarthritic rats subjected to the ankle-bend test. J Neurosci Res. 2006; 83(3): 515–523. PMID: 16400658. DOI: 10.1002/jnr.20737

56. van Nieuwenhuijzen, P.S.; McGregor, I.S.; Hunt, G.E. The distribution of γ-hydroxybutyrate-induced Fos expression in rat brain: Comparison with baclofen. Neuroscience.2009; 158(2): 441–455. DOI: 10.1016/j.neuroscience.2008.10.011. ISSN 0306-4522. PMID 18996447.

57. Kumru H., Albu S., Kofler M. , Vidal J. The long-term analgesic effect of intrathecal baclofen on neuropathic pain in patients with spinal cord injury. neurologia. 2020 Jan 14. pii: S0213–4853 (19)30135-5 PMID: 31952888. DOI: 10.1016/j.nrl.2019.09.009

58. Heetla H.W., Proost J.H., Molmans B.H., Staal M. J., van Laar T. A pharmacokinetic–pharmacodynamic model for intrathecal baclofen in patients with severe spasticity. British Journal of Clinical Pharmacology. 2016; 81(1): 101–112. PMID: 27099877. PMCID: PMC4693571. DOI: 10.1111/bcp.12781

59. Dias L.S., Vivek G., Manthappa M., Acharya R.V. Role of hemodialysis in baclofen overdose with normal renal function. Indian J Pharmacol. 2011; 43:722–723. PMID: 22144783. PMCID: PMC3229794. DOI: 10.4103/0253-7613.89835.

60. Bowman A., Ayyangar R., Gonzales I., Hornyak J. Intrathecal baclofen toxicity in a patient with acute kidney injury. J Pediatric Rehabil Med. 2019; 12(3): 313–315. PMID: 31476182. DOI: 10.3233/PRM-180598

61. Sanchez-Ponce R. , Wang L. Q., Lu W., von Hehn J., Cherubini M., Rush R. Metabolic and Pharmacokinetic Differentiation of STX209 and Racemic Baclofen in Humans. Metabolites. 2012; 2(3): 596–613. PMID: 24957649. PMCID: PMC3

4. DOI: 10.3390/metabo2030596.

62. Muanda F. T., Weir M. A., Bathini L., Blake P. G., Chauvin K., Dixon S. N., McArthur E., Sontrop J. M., Moist. Association of Baclofen With Encephalopathy in Patients With Chronic Kidney Disease. JAMA. 2019Nov 9. PMID: 31705755. PMCID: PMC6865230. DOI: 10.1001/jama.2019.17725

63. Chartier M., Tannous S., Benturquia N., Labat L., Reis R., Risède P., Chevillard L., Mégarbane B. Baclofen-Induced Neuro-Respiratory Toxicity in the Rat: Contribution of Tolerance and Characterization of Withdrawal Syndrome Toxicological Sciences. 2018; 164(1): 153–165. PMID: 29945230. DOI: 10.1093/toxsci/kfy073

of the electroencephalographic effect/concentration relationships and contribution of tolerance in the rat. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2018; 86(30): 131–139. PMID: 29782961. DOI: 10.1016/j.pnpbp.2018.05.016

65. Mikhailov A.Yu., Berezina I.Yu. Potskhveria M.M., Sumsky L.I. Electroencephalogram simulating brain death in acute baclofen poisoning. Emergency medical care. Journal them. N.V. Sklifosovsky. 2017; 8(6): 371–375. DOI: 10.23934/2223-9022-2017-6-4-371-375

66. Ostermann M.E., Young B., Sibbald W.J., Nicole M.W. Coma mimicking brain death following baclofen overdose. Intensive Care Med. 2000; 26:1144–1146. PMID: 11030173. DOI: 10.1007/s001340051330

67. Salazar M.L., Eiland L.S. Intrathecal baclofen withdrawal resembling serotonin syndrome in an adolescent boy with cerebral palsy. Pediatric Emerge Care. 2008; 24(10): 691–693. PMID: 19240673. DOI: 10.1097/PEC.0b013e318188a952

68. Mohammed I., Hussain A. Intrathecal baclofen withdrawal syndromea life-threatening complication of baclofen pump: a case report. BMC Clinic Pharmacol. 2004; 4: 6. PMID: 15301690. PMCID: PMC514562 DOI: 10.1186/1472-6904-4-6

69. Hansen C.R., Gooch J.L., Such-Neibar T. Prolonged, severe intrathecal baclofen withdrawal syndrome: a case report. Arch Phys Med Rehabil. 2007; 88(11): 1468–1471. PMID: 17964889. DOI: 10.1016/j.apmr.2007.07.021

70. Motta F., Antonello C.E. Analysis of complications in 430 consecutive pediatric patients treated with intrathecal baclofen therapy: 14-year experience. J Neurosurge Pediatr. March 2014; 13(3): 301–306. DOI: 10.3171/2013.11.PEDS13253.

71. Defayette A., Perrello A., Brewer T., Picano J., Ahmed S. Enteral baclofen withdrawal managed with intravenous dexmedetomidine: A case report. Am J Health Syst Pharm. 2020 Jan 13. pii: zxz332. PMID: 31930325. DOI: 10.1093/ajhp/zxz332

72. Richter E.K., Baldovini A., Gandía Blasco V.M., Leone M., Albanese J. About baclofen withdrawal syndrome. Press Med. 2016; 45(5): 547–548. PMID: 27016853. DOI: 10.1016/j.lpm.2016.02.012

73. Alden T.D., Lytle R.A., Park T.S., Noetzel M.J., Ojemann J.G. Intrathecal baclofen withdrawal: a case report and review of the literature. Child’s Nerv Syst. 2002; 18(9–10): 522–525. Epub 2002 Jul 23. PMID: 12382179. DOI: 10.1007/s00381-002-0634-8

74. Shirley K.W., Kothare S., Piatt J.H Jr, Adirim T.A. Intrathecal baclofen overdose and withdrawal. Pediatric Emerge Care. 2006; 22(4): 258–261. PMID: 16651918. DOI: 10.1097/01.pec.0000210175.40763.c5

75. Roberge R.J., Martin T.G., Hodgman M., Benitez J.G., Brunswick J.E. Supraventricular tachyarrhythmia associated with baclofen overdose. Clin Toxil 1994; 32:291–297. PMID: 8007036. DOI: 10.3109/1556365940

61

76. Katyal R., Samkutty D., Muzammil S.M., Saucedo S. Baclofen toxicity presenting as myoclonic status epilepticus. Neurol Clin Pract. 2019Dec; 9(6): 516–518. DOI: 10.1212/CPJ.0000000000000686. PMID: 32042496

77. Rolland B., Deheul S., Danel T., Bordet R., Cottencin O. A case of de novo seizures following a probable interaction of high-dose baclofen with alcohol. Alcohol Alcohol. 2012; 47(5): 577–580. PMID: 22753796. DOI: 10.1093/alcalc/ags076

78.